|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zou XN, Duan JJ, Huangfu XM, Chen WQ and
Zhao P: Analysis of stomach cancer mortality in the national
retrospective sampling survey of death causes in China, 2004-2005.
Zhonghua Yu Fang Yi Xue Za Zhi. 44:390–397. 2010.(In Chinese).
PubMed/NCBI
|
|
3
|
Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J
and Sung JJ: Dysregulation of cellular signaling in gastric cancer.
Cancer Lett. 295:144–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ooi CH, Ivanova T, Wu J, Lee M, Tan IB,
Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, et al: Oncogenic
pathway combinations predict clinical prognosis in gastric cancer.
PLoS Genet. 5:e10006762009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jonkers J, Korswagen HC, Acton D, Breuer M
and Berns A: Activation of a novel proto-oncogene, Frat1,
contributes to progression of mouse T-cell lymphomas. EMBO J.
16:441–450. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Y, Hewitt SM, Liu S, Zhou X, Zhu H,
Zhou C, et al: Tissue microarray analysis of human FRAT1 expression
and its correlation with the subcellular localisation of
beta-catenin in ovarian tumours. Br J Cancer. 94:686–691.
2006.PubMed/NCBI
|
|
7
|
Wang Y, Liu S, Zhu H, Zhang W, Zhang G,
Zhou X, Zhou C, Quan L, Bai J, Xue L, et al: FRAT1 overexpression
leads to aberrant activation of beta-catenin/TCF pathway in
esophageal squamous cell carcinoma. Int J Cancer. 123:561–568.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo G, Mao X, Wang P, Liu B, Zhang X,
Jiang X, Zhong C, Huo J, Jin J and Zhuo Y: The expression profile
of FRAT1 in human gliomas. Brain Res. 1320:152–158. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saitoh T and Katoh M: FRAT1 and FRAT2,
clustered in human chromosome 10q24.1 region, are up-regulated in
gastric cancer. Int J Oncol. 19:311–315. 2001.PubMed/NCBI
|
|
10
|
Yu QG, Gu W, Wang SY, Zhang XX, Yang ZR
and Li WS: Establishment of FRAT1 gene silence HT29 cells model by
RNA interference. China Mod Med. 21:12–15. 2014.
|
|
11
|
Jonkers J, van Amerongen R, van der Valk
M, Robanus-Maandag E, Molenaar M, Destrée O and Berns A: In vivo
analysis of Frat1 deficiency suggests compensatory activity of
Frat3. Mech Dev. 88:183–194. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yost C, Farr GH III, Pierce SB, Ferkey DM,
Chen MM and Kimelman D: GBP, an inhibitor of GSK-3, is implicated
in Xenopus development and oncogenesis. Cell. 93:1031–1041. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liebner S and Plate KH: Differentiation of
the brain vasculature: the answer came blowing by the Wnt. J
Angiogenes Res. 2:12010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ille F and Sommer L: Wnt signaling:
multiple functions in neural development. Cell Mol Life Sci.
62:1100–1108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reis M and Liebner S: Wnt signaling in the
vasculature. Exp Cell Res. 319:1317–1323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saitoh T, Mine T and Katoh M: Molecular
cloning and expression of proto-oncogene FRAT1 in human cancer. Int
J Oncol. 20:785–789. 2002.PubMed/NCBI
|
|
18
|
Zhang Y, Han Y, Zheng R, Yu JH, Miao Y,
Wang L and Wang EH: Expression of Frat1 correlates with expression
of β-catenin and is associated with a poor clinical outcome in
human SCC and AC. Tumour Biol. 33:1437–1444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chiurillo MA: Role of the Wnt/β-catenin
pathway in gastric cancer: An in-depth literature review. World J
Exp Med. 5:84–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jonkers J, Weening JJ, van der Valk M,
Bobeldijk R and Berns A: Overexpression of Frat1 in transgenic mice
leads to glomerulosclerosis and nephrotic syndrome, and provides
direct evidence for the involvement of Frat1 in lymphoma
progression. Oncogene. 18:5982–5990. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo G, Kuai D, Cai S, Xue N, Liu Y, Hao J,
Fan Y, Jin J, Mao X, Liu B, et al: Knockdown of FRAT1 expression by
RNA interference inhibits human glioblastoma cell growth, migration
and invasion. PLoS One. 8:e612062013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo G, Zhong CL, Liu Y, Mao XG, Zhang Z,
Jin J, et al: Overexpression of FRAT1 is associated with malignant
phenotype and poor prognosis in human gliomas. Dis Markers.
2015:2897502015. View Article : Google Scholar : PubMed/NCBI
|
